Loading company
Lipocine Inc.
LPCN · Nasdaq · ·
Next earnings: November 5, 2026
$2.15+2.6%Sep 29 close
- 1M
- -1.2%
- 6M
- -71.7%
- 1Y
- -24.7%
- 5Y
- -88.6%
LPCN · Nasdaq · ·
Next earnings: November 5, 2026
$2.15+2.6%Sep 29 close
Lipocine Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $190.1K | $622.8K | -69.48% |
| Profit | -$2.6M | -$2.2M | -18.90% |
| Profit per share | -$0.32 | -$0.41 | +21.95% |
| Free Cash Flow | $1.7M | -$3.9M | +143.03% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. Lipocine’s development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Lipocine Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Lipocine Inc. has no earnings call transcript available.